Recent findings showed that the KRAS G12D mutation leads to aggressive phenotype of MPN through mediation of Sos1, suggesting the use of Sos1-oncogenic Kras interaction as new therapeutic targets [93]. Here, KRAS is linked to myeloproliferative neoplasm.